ClinicalTrials.gg
CompletedNCT00539890Updated Oct 14, 2009

Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Technosphere Insulin in Diabetes Type 2, sponsored by Mannkind Corporation. Completed at 33 sites in Russian Federation. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2009-10-14.

Sponsored by Mannkind Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.

Enrollment
49th of 49
0 · median 129
Started
2005
with 1 other
Phase 3
25 of 49
none open now
Registered
23rd of 49
by date
Lead sponsor
13 of 49
Mannkind Corporation

Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 49th largest by enrollment, is one of 2 that started in 2005, is one of 25 in phase 3, and was the 23rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 as a file.
02

Study summary

To compare the efficacy of prandial TI plus basal insulin versus prandial rapid acting, subcutaneous insulin plus basal insulin in subjects with type 2 diabetes who had an HbA1c >7.0% and \<11.5%.

03

Conditions studied

  • Diabetes Type 2
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 2 years since diagnosis of type 2 diabetes mellitus
  • Received subcutaneous (sc) insulin for at least 3 months
  • \<44 kg/m2
  • >7.0% and \<11.5%
  • Serum creatinine \<2.0 mg/dL for males and \<1.8 mg/dL for females
  • Baseline FVC and >70% and \< 125% of predicted normal

Exclusion criteria

Exclusion Criteria:

  • Significant hepatic disease (/ALT3 x )
  • Diagnosis of Type 1 diabetes
  • Severe complications of diabetes
  • History of moderate to severe ketoacidosis within the past 3 months
  • Upper respiratory infection in the last 15 days or a lower respiratory infection in the past 30 days
  • Diagnosis of
  • Positive serology for or C
  • , emphysema, or asthma
  • Current smokers or smoking history within the past 6 months
  • Major psychiatric disorder precluding satisfactory completion of protocol
  • heart disease disease, stroke or heart attack within the past 6 months
  • Treatment with an drug within 30 days
  • Previous treatment with Technosphere/Insulin
  • History of in the past 5 years except basal cell carcinoma
  • Anemia ( \<10.5 g/dL for females and \<11.5 g/dL (for males)
  • Women who were pregnant of lactating
  • History of to drugs resembling FDKP carrier products
  • Treatment with another inhaled insulin product during the duration of the study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change in HbA1c from baseline to treatment week 24

    Time frame: 24 weeks

07

Study locations

33 sites
  • Ural State Medical Academy of Post-Graduate Education Municipal Clinical Hospital # 3
    Chelyabinsk, RUS 454021, Russian Federation
  • NHI Kemerovo Regional Clinical Hospital
    Kemerovo, RUS 650061, Russian Federation
  • NI Principal Military Clinical Hospital n a academician N.N. Burdenko of the Ministry of Defense
    Moscow, RUS 105229, Russian Federation
  • Moscow State Medico-Stomatological University City Hospital # 23
    Moscow, RUS 109240, Russian Federation
  • Russian State Medical University
    Moscow, RUS 109263, Russian Federation
  • Clinical Research Institute of Physic-Chemical Medicine Hospital # 29
    Moscow, RUS 111020, Russian Federation
  • NEI HPE Moscow State University of Medicine and Dentistry of FAHSD City Clinical Hospital #70
    Moscow, RUS 111399, Russian Federation
  • Russian State Medical University City Hospital # 4
    Moscow, RUS 113093, Russian Federation
  • Russian Academy of Medical Sciences National Research Ctr for Endocrinology Institute of Diabetes
    Moscow, RUS 117036, Russian Federation
  • Moscow Hospital of Glavmosstroy State Unitary Enterprise Medical Centre Medical Sanitary Unit #47
    Moscow, RUS 117192, Russian Federation
  • Russian State Medical University Central Clinical Hospital Russian Science Academy
    Moscow, RUS 117593, Russian Federation
  • Sechenov Moscow Medical Academy
    Moscow, RUS 119881, Russian Federation
  • Moscow Medical Academy
    Moscow, RUS 123478, Russian Federation
  • Moscow, RUS 125315, Russian Federation
  • SIH of Moscow City Clinical Hopsital #81 Endocrinology and Diabetology
    Moscow, RUS 127644, Russian Federation
  • Moscow State Medical Stomatology University Municipal Hospital # 63 Endocrinology Diabetology
    Moscow, RUS 129090, Russian Federation
  • Moscow City Clinical Hospital # 20
    Moscow, RUS 129327, Russian Federation
  • Municipal Clinical Hospital #13
    Moscow, RUS 150062, Russian Federation
  • Nizhni Novgorod regional hospital na Semashko
    N Novgorod, RUS 603126, Russian Federation
  • Center Diabetes LLC
    Samara, RUS 443067, Russian Federation
  • Saratov City Outpatient Clinic # 20
    Saratov, RUS 410038, Russian Federation
  • Saratov Medical University Faculty Therapy Chair Clinical Hospital # 3
    Saratov, RUS 410054, Russian Federation
  • NEI HPE Smolensk State Medical Academy of FAHSD RNHI Smolensk Regional Clinical Hospital
    Smolensk, RUS 214018, Russian Federation
  • St Petersburg NHI City Polytclinic #77 City Diabetological Center #4
    St Petersburg, RUS 193012, Russian Federation
  • Central Medical Sanitary Unit #122
    St Petersburg, RUS 194291, Russian Federation
  • SPb Diabetological Center
    St Petersburg, RUS 194354, Russian Federation
  • St Petersburg Medical Academy St Elizabeth Hospital
    St Petersburg, RUS 195257, Russian Federation
  • Pavlov State Medical Univ of St Petersburg
    St Petersburg, RUS 197022, Russian Federation
  • City Outpatient Clinic # 34
    St Petersburg, RUS 197198, Russian Federation
  • TUV Medico-Military Academy
    St Petersburg, RUS 198013, Russian Federation
  • St Petersburg NHI Municipal Multi-Speciality Hospital # 2
    St. Petersburg, RUS 194354, Russian Federation
  • MHI Clinical Hospital for Emergency Care na NV Soloviev
    Yaroslavl, RUS 150003, Russian Federation
  • Yaroslavl Regional Clinical Hospital
    Yaroslavl, RUS 150062, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2007
First posted
Oct 5, 2007
Start
Nov 2005
CompletionActual
Jul 2006
Last update
Oct 14, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00539890
First posted
Oct 5, 2007
Start date
Nov 2005
Completion
Jul 2006
Last update
Oct 14, 2009

Study contacts

Robert Baughman, PhD
study director · Mannkind Corporation
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion